After studying changes in IGFBP2 and IGFBP3 levels in serial postoperative serum samples from prostate cancer in patients with and without relapse, Yu et al [91] suggested that IGFBP2 may play a role in the progression of prostate cancer, but that serum levels of IGF-I and IGFBP3 have no predictive value in the progression of prostate cancer. The gene discussed is IGF1; the disease is prostate cancer.